Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465835 · ClinicalTrials.gov registry record · Phase 1
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
A Phase 1 study of T Cell Malignancies, sponsored by Electra Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT07465835: Recruiting Phase 1 study of T Cell Malignancies, sponsored by Electra Therapeutics.
NCT07465835 is a Phase 1 study of T Cell Malignancies that is actively recruiting participants, run by Electra Therapeutics. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07465835, a Phase 1 study of T Cell Malignancies, is actively recruiting participants, sponsored by Electra Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Primary Outcome
Incidence of DLTs and treatment emergent adverse events (TEAEs), including serious adverse advents (SAEs)
Conditions Studied
Interventions
- DRUG ELA026
Study Locations (1)
Michigan
- START, Midwest - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2026-02-17 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT07465835 shows while recruiting
NCT07465835 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).
The record links to 1 condition, with T Cell Malignancies appearing as the primary indexed condition, and to 1 intervention - of which ELA026 is the first listed.
NCT07465835 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07465835 about?
NCT07465835 is a clinical study titled "A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)". This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
What is the current status of trial NCT07465835?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2026-02-17. Estimated completion is 2028-12.
What conditions does trial NCT07465835 study?
This clinical trial studies the following conditions: T Cell Malignancies.
What interventions are being tested in trial NCT07465835?
The interventions under investigation include: ELA026 (DRUG).
Who is sponsoring clinical trial NCT07465835?
This trial is sponsored by Electra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07465835 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07465835's enrollment target sits among peer trials
84 660th of 2000 higher than 1,336 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI